Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.ATHA · Entity 1487 | Chief Financial Officer | January 19, 2023 | January 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date January 19, 2023 · Filed January 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2033-01-18 | Direct | 150,000 |
Reported balance
After 2023-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-19 · Grant · Acquired 150,000 · Balance 150,000 F1: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2023 Filed Jan 23, 2023 22:51 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001209191-23-004478 · doc4.xml · derivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-18 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 21:58 UTC | LeonaBio, Inc. ATHA · Entity 1487 | PurchaseCommon Stock | 50,000 | $2.85 | $142,250.00 |
DisclosureSEC source: 0001209191-22-063009 · doc4.xml · nonDerivative · entry 2 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,930 F4 · price: The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.93 to $2.98, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range. Read SEC document |
| November 18, 2022 Filed Dec 30, 2022 21:58 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 763 | $2.74 | $2,090.62 |
DisclosureSEC source: 0001209191-22-063009 · doc4.xml · nonDerivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,930 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 23:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | SaleCommon Stock | 2,614 | $2.69 | $7,031.66 |
DisclosureSEC source: 0001209191-22-039342 · doc4.xml · nonDerivative · entry 3 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,167 F5 · kind: The reported shares were sold to cover the Issuer's tax withholding obligations in connection with the vesting of RSUs. Such sale was made pursuant to an Issuer-mandated policy and was not subject to discretion. F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $2.62 to $2.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 23:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039342 · doc4.xml · nonDerivative · entry 2 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,781 F4 · shares: On November 3, 2021, the reporting person was granted restricted stock units ("RSUs") representing 30,000 shares of Common Stock of the Issuer. The RSUs were scheduled to vest according to the following schedule: (1) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's ACT-AD Phase 2 clinical trial; (2) one third (1/3rd) of the number of shares subject to the RSU award vest at the completion of the public readout of topline results of the Issuer's LIFT-AD Phase 2/3 clinical trial (the "LIFT-AD Readout") and (3) one third (1/3rd) of the number of shares subject to the RSU award vest six (6) months after the LIFT-AD Readout, in each case subject to continued service with the Issuer through the applicable vesting date. On June 22, 2022, the Issuer completed the public readout of topline results of the ACT-AD Phase 2 clinical trial and 10,000 RSUs vested and settled on such date. Read SEC document |
| May 18, 2022 Filed Jun 24, 2022 23:53 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 1,721 | $7.06 | $12,150.26 |
DisclosureSEC source: 0001209191-22-039342 · doc4.xml · nonDerivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,781 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of November 18, 2021 through May 18, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2022 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began November 18, 2021. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on May 18, 2022. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 23:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001209191-22-024219 · doc4.xml · derivative · entry 2 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,000 Underlying: Common Stock · 3,000 shares Expires 2032-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 23:36 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 3,000 | $10.64 | $31,920.00 |
DisclosureSEC source: 0001209191-22-024219 · doc4.xml · nonDerivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2022 Filed Jan 20, 2022 22:28 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001209191-22-004123 · doc4.xml · derivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-01-17 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the shares subject to the option will vest on February 18, 2022, and one forty-eighth of the shares subject to the option will vest each month thereafter. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:08 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,305 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-22-002218 · doc4.xml · derivative · entry 3 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,305 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option fully vested on January 1, 2022. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 22:08 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 6,305 | $1.35 | $8,511.75 |
DisclosureSEC source: 0001209191-22-002218 · doc4.xml · nonDerivative · entry 2 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2021 Filed Jan 6, 2022 22:08 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 931 | $12.51 | $11,646.81 |
DisclosureSEC source: 0001209191-22-002218 · doc4.xml · nonDerivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,755 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021. Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 22:48 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,305 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-21-039627 · doc4.xml · derivative · entry 3 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,305 Underlying: Common Stock · 6,305 shares Expires 2028-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option fully vested on January 1, 2021. Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 22:48 UTC | LeonaBio, Inc. ATHA · Entity 1487 | Exercise / conversionCommon Stock | 6,305 | $1.35 | $8,511.75 |
DisclosureSEC source: 0001209191-21-039627 · doc4.xml · nonDerivative · entry 2 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2021 Filed Jun 10, 2021 22:48 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantCommon Stock | 1,554 | $14.45 | $22,455.30 |
DisclosureSEC source: 0001209191-21-039627 · doc4.xml · nonDerivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,519 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of October 2, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · date: The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began October 2, 2020. F3 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 22:38 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 73,500 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001209191-21-012822 · doc4.xml · derivative · entry 1 MILESON GLENNA · CIK 0001822241 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 73,500 shares Expires 2031-02-17 F1 · derivative.exercise_date: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.